Clinical Trial

Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated June 13, 2025 (before its estimated November 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this multicenter, two-stage, open-label study is to investigate the safety, immunogenicity, and efficacy of ANB-002 in subjects with hemophilia В. The study will have a dose-escalation design with elements of phase I/II seamless adaptive design.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-11-04; most recent amendment 2025-06-10.
Trial Details
NCT Number NCT06120582
Lead Sponsor Biocad
Conditions Hemophilia B
Enrollment 28 participants
Start Date 2023-05-02
Primary Completion 2025-11 (estimated)
Study Completion 2029-11 (estimated)
Updated on ClinicalTrials.gov 2025-06-13